Table 3.
Generalized linear mixed model regression results for dimensional ratings of evaluator-rated symptoms from baseline to 27 weeks.
| ALIFE PSR Depression | CDRS-R Total | YMRS | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Estimates | 95% CI | p | Estimates | 95% CI | p | Estimates | 95%CI | p | |
| Baseline (N=21) |
4.33 | Lo 3.83 Hi 4.83 |
<0.001 | 57.43 | Lo 51.58 Hi 63.27 |
<0.001 | 20.52 | Lo 17.59 Hi 23.46 |
<0.001 |
| Mid-Treatment (N=21) |
−0.71 | Lo −1.22 Hi −0.21 |
0.006 | −14.76 | Lo −20.77 Hi −8.75 |
<0.001 | −4.9 | Lo −7.78 Hi −2.03 |
0.001 |
| Post-Treatment (N=20) |
−1.53 | Lo −2.05 Hi −1.02 |
<0.001 | −20.71 | Lo −27.28 Hi −14.14 |
<0.001 | −7.36 | Lo −10.51 Hi −4.22 |
<0.001 |
| Follow-up (N=19) |
−1.7 | Lo −2.24 Hi −1.17 |
<0.001 | −20.38 | Hi −26.70 Lo −14.07 |
<0.001 | −7.12 | Lo −10.14 Hi −4.10 |
<0.001 |
Note: Mid-Treatment = 9 weeks, Post-Treatment = 18 weeks, Follow-up = 27 weeks. The p-values associated with baseline indicate the degree to which scores are higher than zero.